|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 377.05 EUR | -0.41% |
|
-0.72% | +2.81% |
| 07-09 | LOREAL : JP Morgan remains Neutral | ZD |
| 07-08 | LOREAL : Buy rating from UBS | ZD |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 32.29B | 38.26B | 41.18B | 43.49B | 44.05B | |||||
Total Revenues | 32.29B | 38.26B | 41.18B | 43.49B | 44.05B | |||||
Cost of Goods Sold, Total | 8.43B | 10.58B | 10.77B | 11.23B | 11.31B | |||||
Gross Profit | 23.85B | 27.68B | 30.42B | 32.26B | 32.74B | |||||
Selling General & Admin Expenses, Total | 16.68B | 19.09B | 20.99B | 22.23B | 22.48B | |||||
R&D Expenses | 1.03B | 1.14B | 1.29B | 1.35B | 1.38B | |||||
Other Operating Expenses, Total | 17.7B | 20.23B | 22.27B | 23.58B | 23.86B | |||||
Operating Income | 6.15B | 7.45B | 8.14B | 8.68B | 8.88B | |||||
Interest Expense, Total | -38M | -70.4M | -227M | -373M | -366M | |||||
Interest And Investment Income | 397M | 538M | 583M | 593M | 520M | |||||
Net Interest Expenses | 359M | 468M | 356M | 220M | 154M | |||||
Income (Loss) On Equity Invest. | 600K | 1.4M | 200K | -1.3M | -5.5M | |||||
Other Non Operating Income (Expenses) | -30.1M | -65.8M | -46.6M | -25.8M | -29M | |||||
EBT, Excl. Unusual Items | 6.48B | 7.85B | 8.45B | 8.87B | 9B | |||||
Restructuring Charges | -150M | -58M | -88.5M | -237M | -208M | |||||
Merger & Related Restructuring Charges | -14.3M | - | -46M | -20.7M | -49.5M | |||||
Impairment of Goodwill | -255M | - | -250M | - | - | |||||
Gain (Loss) On Sale Of Assets | -400K | -122M | -6.7M | -15.2M | -37.7M | |||||
Asset Writedown | -82.8M | -39M | -20.6M | -50.8M | - | |||||
Legal Settlements | 45.6M | - | - | -99.9M | - | |||||
Other Unusual Items | 24.2M | -22.5M | -38.1M | -14M | -210M | |||||
EBT, Incl. Unusual Items | 6.05B | 7.61B | 8B | 8.43B | 8.5B | |||||
Income Tax Expense | 1.45B | 1.9B | 1.81B | 2.02B | 2.36B | |||||
Earnings From Continuing Operations | 4.6B | 5.71B | 6.19B | 6.42B | 6.13B | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 4.6B | 5.71B | 6.19B | 6.42B | 6.13B | |||||
Minority Interest | -5.1M | -6M | -6.5M | -7.8M | -6.5M | |||||
Net Income - (IS) | 4.6B | 5.71B | 6.18B | 6.41B | 6.13B | |||||
Net Income to Common Incl Extra Items | 4.6B | 5.71B | 6.18B | 6.41B | 6.13B | |||||
Net Income to Common Excl. Extra Items | 4.6B | 5.71B | 6.18B | 6.41B | 6.13B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 8.24 | 10.65 | 11.55 | 11.99 | 11.48 | |||||
Basic EPS - Continuing Operations | 8.24 | 10.65 | 11.55 | 11.99 | 11.48 | |||||
Basic Weighted Average Shares Outstanding | 558M | 536M | 535M | 534M | 534M | |||||
Net EPS - Diluted | 8.21 | 10.61 | 11.52 | 11.95 | 11.44 | |||||
Diluted EPS - Continuing Operations | 8.21 | 10.61 | 11.52 | 11.95 | 11.44 | |||||
Diluted Weighted Average Shares Outstanding | 560M | 538M | 537M | 536M | 535M | |||||
Normalized Basic EPS | 7.25 | 9.15 | 9.85 | 10.36 | 10.53 | |||||
Normalized Diluted EPS | 7.23 | 9.12 | 9.82 | 10.33 | 10.5 | |||||
Dividend Per Share | 4.8 | 6 | 6.6 | 7 | 7.2 | |||||
Payout Ratio | 51.16 | 47.14 | 55.39 | 56.41 | 63.93 | |||||
American Depositary Receipts Ratio (ADR) | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |||||
Supplemental Items | ||||||||||
EBITDA | 6.93B | 8.29B | 9.01B | 9.64B | 9.89B | |||||
EBITA | 6.22B | 7.46B | 8.21B | 8.74B | 8.94B | |||||
EBIT | 6.15B | 7.45B | 8.14B | 8.68B | 8.88B | |||||
Effective Tax Rate - (Ratio) | 23.9 | 24.95 | 22.63 | 23.9 | 27.81 | |||||
Total Current Taxes | 1.36B | 2B | 1.91B | 2.05B | 2.29B | |||||
Total Deferred Taxes | 83.6M | -96.5M | -95.3M | -37.4M | 68.2M | |||||
Normalized Net Income | 4.04B | 4.9B | 5.28B | 5.54B | 5.62B | |||||
Non-Cash Pension Expense | -15.5M | -9.1M | -11.3M | 2.1M | 3.3M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 10.59B | 12.06B | 13.36B | 14.01B | 14.18B | |||||
Selling and Marketing Expenses | 10.59B | 12.06B | 13.36B | 14.01B | 14.18B | |||||
Research And Development Expense From Footnotes | 1.03B | 1.14B | 1.29B | 1.35B | 1.38B | |||||
Stock-Based Comp., Other (Total) | 155M | 169M | 168M | 239M | 248M | |||||
Total Stock-Based Compensation | 155M | 169M | 168M | 239M | 248M |
- Stock Market
- Stocks
- OR Stock
- Financials L'Oréal
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















